Cancer Medicine (Aug 2019)
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
- Barbara Mora,
- Elisa Rumi,
- Paola Guglielmelli,
- Daniela Barraco,
- Margherita Maffioli,
- Alessandro Rambaldi,
- Marianna Caramella,
- Rami Komrokji,
- Jason Gotlib,
- Jean Jacques Kiladjian,
- Francisco Cervantes,
- Timothy Devos,
- Francesca Palandri,
- Valerio DeStefano,
- Marco Ruggeri,
- Richard T. Silver,
- Giulia Benevolo,
- Francesco Albano,
- Chiara Cavalloni,
- Daniela Pietra,
- Tiziano Barbui,
- Giada Rotunno,
- Mario Cazzola,
- Alessandro Maria Vannucchi,
- Toni Giorgino,
- Francesco Passamonti
Affiliations
- Barbara Mora
- Hematology, Department of Medicine and Surgery University of Insubria Varese Italy
- Elisa Rumi
- Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo, Università di Pavia Pavia Italy
- Paola Guglielmelli
- CRIMM‐Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine Azienda ospedaliera‐Universitaria Careggi, University of Florence Florence Italy
- Daniela Barraco
- Hematology, Department of Medicine and Surgery University of Insubria Varese Italy
- Margherita Maffioli
- Hematology, Department of Medicine and Surgery University of Insubria Varese Italy
- Alessandro Rambaldi
- Hematology and BMT Unit ASST Papa Giovanni XXIII, University of Milan Bergamo Italy
- Marianna Caramella
- Ospedale Niguarda Cà Granda Milano Italy
- Rami Komrokji
- Moffit Cancer Center Tampa Florida
- Jason Gotlib
- Stanford University Palo Alto California
- Jean Jacques Kiladjian
- Hôpital Saint‐Louis et Université Paris Diderot Paris France
- Francisco Cervantes
- Hospital Clínic, IDIBAPS, University of Barcelona Barcelona Spain
- Timothy Devos
- Department of Hematology, University Hospitals Leuven and Laboratory of Experimental Transplantation, Department of Microbiology and Immunology KU Leuven Leuven Belgium
- Francesca Palandri
- Policlinico S. Orsola‐Malpighi Bologna Italy
- Valerio DeStefano
- Università Cattolica del Sacro Cuore Roma Italy
- Marco Ruggeri
- Ospedale S. Bortolo Vicenza Italy
- Richard T. Silver
- Weill Cornell Medical College New York
- Giulia Benevolo
- Centro Oncologico Ematologico Subalpino (COES) Torino Italy
- Francesco Albano
- Università di Bari Bari Italy
- Chiara Cavalloni
- Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo, Università di Pavia Pavia Italy
- Daniela Pietra
- Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo, Università di Pavia Pavia Italy
- Tiziano Barbui
- FROM Research Foundation ASST Papa Giovanni XXIII Bergamo Italy
- Giada Rotunno
- CRIMM‐Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine Azienda ospedaliera‐Universitaria Careggi, University of Florence Florence Italy
- Mario Cazzola
- Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo, Università di Pavia Pavia Italy
- Alessandro Maria Vannucchi
- CRIMM‐Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine Azienda ospedaliera‐Universitaria Careggi, University of Florence Florence Italy
- Toni Giorgino
- Biophysics Institute, National Research Council of Italy Milan Italy
- Francesco Passamonti
- Hematology, Department of Medicine and Surgery University of Insubria Varese Italy
- DOI
- https://doi.org/10.1002/cam4.2107
- Journal volume & issue
-
Vol. 8,
no. 9
pp. 4089 – 4092
Abstract
Abstract Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient‐years. When including non‐melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient‐years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.
Keywords
